{"title":"PharmaNews","authors":"","doi":"10.1159/000506143","DOIUrl":"https://doi.org/10.1159/000506143","url":null,"abstract":"Auch im klinischen Alltag profitieren Patienten mit mittelschwerer bis schwerer Psoriasis deutlich von der Behandlung mit dem Interleukin (IL)-17A-Inhibitor Cosentyx® (Secukinumab). Die in den klinischen Studien dokumentierten Ergebnisse lassen sich auch im Behandlungsalltag realisieren, wie 3 nichtinterventionelle Studien zeigen, die bei der Jahrestagung der European Academy of Dermatology and Venereology (EADV) präsentiert wurden. Unter der Therapie mit Cosentyx verbesserte sich sowohl die Hautsymptomatik als auch die Lebensqualität von Patienten und ihren Angehörigen erheblich [1, 2].","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133526940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psoriasis: IL-17A-Inhibitor zeigt gute Langzeitwirksamkeit","authors":"N. Kirsten","doi":"10.1159/000505200","DOIUrl":"https://doi.org/10.1159/000505200","url":null,"abstract":"Background: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate-to-severe psoriasis and psoriatic arthritis. Objective: To assess the efficacy and safety of secukinumab through 5 years of treatment in moderate-to-severe psoriasis. Methods: In the core SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving subcutaneous secukinumab until Year 1. Thereafter, patients entered the extension phase and continued treatment as per the core trial. Treatment was double-blinded until the end of Year 3 and open-label from Year 4. Here, we focus on the 300 mg fixed-interval (every 4 weeks) treatment, the recommended per label dose. Efficacy data are primarily reported as observed, but multiple imputation (MI) and last observation carried forward (LOCF) techniques were also undertaken as supportive analyses. Results: At Year 1, 168 patients entered the extension study and at the end of Year 5, 126 patients completed 300 mg (every 4 weeks) treatment. PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%). PASI responses were consistent regardless of the analysis undertaken (as observed, MI, or LOCF). The average improvement in mean PASI was approximately 90% through 5 years compared with core study baseline. DLQI (dermatology life quality index) 0/1 response also sustained through 5 years (72.7% at Year 1 and 65.5% at Year 5). The safety profile of secukinumab remained favourable, with no cumulative or unexpected safety concerns identified. Conclusion: Secukinumab 300 mg treatment delivered high and sustained levels of skin clearance and improved quality of life through 5 years in patients with moderate-to-severe psoriasis. Favourable safety established in the secukinumab phase 2/3 programme was maintained through 5 years.","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130674627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psoriasis: Wechsel der Medikamentenklasse bei Nichtansprechen?","authors":"S. Philipp","doi":"10.1159/000505056","DOIUrl":"https://doi.org/10.1159/000505056","url":null,"abstract":"Background: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. Methods: This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients. Results: A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p<0.05), achieving PASI 50, 75, and >90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (>2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs. Conclusion: Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"6 6","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132644643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Atopische Dermatitis: Die Frage nach dem Einfluss von Vitaminen bleibt weiter offen","authors":"R. Fölster‐Holst","doi":"10.1159/000505441","DOIUrl":"https://doi.org/10.1159/000505441","url":null,"abstract":"Background: Several studies have suggested that vitamin D (VD) deficiency (VDD) is associated with atopic dermatitis (AD). However, little is known about the relationship between AD and vitamin A (VA). The interaction between VA and VD on AD requires further study. Objective: We detected serum levels of VA and VD in children with AD to explore how VA deficiency (VAD) and VDD affect AD severity. Methods: We assessed the SCORing Atopic Dermatitis (SCORAD) index, total immunoglobin E levels and peripheral blood eosinophil counts. VA and VD levels were determined with high-performance liquid chromatography. Correlations among variables were investigated with Pearson's correlation analysis. Results: The VD and VA levels were significantly lower in children with AD than in normal children (p < 0.001, p = 0.0423). Both VD and VA levels were negatively correlated with SCORAD scores. The SCORAD scores were significantly higher in AD patients with both VDD and VAD (co-deficiency) than in other AD patients. Significant inverse correlations were observed between peripheral blood eosinophil counts and serum VA and VD levels. Conclusions: VA and VD co-deficiency may exacerbate AD symptoms in children, but the specific mechanism underlying this relationship requires further study. These findings may indicate the need for studies evaluating the use of VD and VA as potential treatments for AD patients.","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134127236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hautkrebsscreening: Warum Patienten die Untersuchung meiden","authors":"J. Maschke","doi":"10.1159/000505526","DOIUrl":"https://doi.org/10.1159/000505526","url":null,"abstract":"Background: In 2008, a nationwide standardized and systematic skin cancer screening (SCS) service, which is globally unique, was implemented in Germany. We aimed to provide current data on SCS use, to explore barriers to SCS usage, and to identify population groups with lower rates of SCS use. Methods: We analyzed data from 2.635 participants (18-45 years) in the National Cancer Aid Monitoring on Sunbed Use. Data on SCS use, barriers to SCS, and sociodemographic characteristics were obtained. Chi-square tests and logistic regression analyses were performed to analyze the data. Data was weighted by age, sex, educational level, and federal state. Results: In total, 39.0% of participants reported having been screened for skin cancer at least once in their lifetime. The subjective importance of different barriers varied depending on the participantsʼ educational level. SCS use was negatively associated with male sex (odds ratio (OR) = 0.63, p <0.001), low level of education (OR = 0.83, not significant), immigrant background (OR = 0.63; p <0.001), and having no employment.Conclusion: Although the SCS is part of the regular healthcare services offered in Germany, our data showed lower usage among certain population groups. Barriers relevant for these groups should be considered when developing measures to increase SCS use.","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115486648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Secukinumab in der Behandlung der Plaque-Psoriasis bei Krebspatienten","authors":"Alessio Gambardella","doi":"10.1159/000505283","DOIUrl":"https://doi.org/10.1159/000505283","url":null,"abstract":"Die Datenlage ist zwar widersprüchlich, doch es sieht so aus, als sei Psoriasis mit einem erhöhten Grundrisiko für maligne Erkrankungen assoziiert. Zusätzlich sind verschiedene systemische Psoriasis-Therapien mit einem erhöhten Risiko für maligne Erkrankungen in Zusammenhang gebracht worden. Zur Assoziation von Inhibitoren der Interleukine IL-17 und IL-23 mit der Rate maligner Erkrankungen liegen keine ausreichenden Daten vor, doch bisher sind keine Fälle bekannt. Secukinumab ist ein rekombinanter humaner monoklonaler Immunglobulin-G1/κ-Antikörper, der selektiv an IL-17A bindet; er ist nachweislich wirksam und sicher in der Behandlung von mittelschwerer bis schwerer Psoriasis und somit potenziell geeignet für besonders geschwächte Patienten, die z.B. bereits eine maligne Erkrankung hatten, wie im hier beschriebenen Fall.","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128753190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Inhalt","authors":"F. Wilde","doi":"10.1159/000506142","DOIUrl":"https://doi.org/10.1159/000506142","url":null,"abstract":"1 Einleitung ....................................................................................................... 1 1.1 Zur Zielsetzung der Arbeit ............................................................................... 2 1.2 Zur Eingrenzung der Arbeit ............................................................................. 2 1.3 Zur Vorgehensweise der Arbeit ....................................................................... 2 1.4 Begriffliche Definitionen ................................................................................... 3 1.5 Die bisherige Entwicklung des Kreuzfahrtsektors ............................................ 7","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122716554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Kaleidoskop","authors":"","doi":"10.1159/000505251","DOIUrl":"https://doi.org/10.1159/000505251","url":null,"abstract":"Ein Team der Technischen Universität München (TUM) hat ein von biologischen Vorbildern inspiriertes System aus künstlicher Haut und Steuerungsalgorithmen entwickelt. Dadurch konnte erstmals ein menschengroßer autonomer Roboter großflächig mit künstlicher Haut versehen werden. Die von Prof. Gordon Cheng, Professor für Kognitive Systeme an der TUM, und seinem Team entwickelte künstliche Haut setzt sich aus sechseckigen Zellen zusammen, die etwa die Größe einer 2-Euro-Münze haben. Jede ist mit einem Mikroprozessor und Sensoren ausgestattet, die Berührung, Beschleunigung, Annäherung und Temperatur messen. Durch solche künstliche Haut können Roboter ihre Umwelt viel detaillierter und feinfühliger wahrnehmen. Das hilft ihnen nicht nur dabei, sich sicher zu bewegen. Es sorgt auch dafür, dass die Maschinen Kompass Dermatol 2020;8:37–40 DOI: 10.1159/000505251","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"116 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124230421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
